Growth ⏱ Half-life: Approximately 10-20 minutes — significantly shorter than modified GHRH analogs due to DPP-IV degradation. Discontinued

Sermorelin

Sermorelin Acetate (GRF 1-29)

Updated March 15, 2026

Evidence at a Glance

Regulatory statusDiscontinued
FDA-approved as Geref (1997) for GH deficiency; brand discontinued 2008 for commercial reasons; now compounded-only.
Human evidenceModerate
Animal evidenceModerate

A GHRH(1-29) analog once FDA-approved as Geref for growth hormone deficiency, discontinued in 2008 for commercial (not safety) reasons and now sold only as an unapproved compounded product.

What the research does not support

  • The branded FDA-approved product no longer exists; compounded sermorelin is not an FDA-approved drug.
  • Its approval was for growth hormone deficiency, not anti-aging, fat loss, or bodybuilding.
  • It stimulates the body's own GH pulses rather than delivering HGH, and performance benefits are unproven.
  • It has not been shown to extend lifespan or reverse aging.
Half-Life
Approximately 10-20 minutes — significantly shorter than modified GHRH analogs due to DPP-IV degradation.
Mol. Weight
3357.93 g/mol

What is Sermorelin?

Sermorelin is the synthetic version of the biologically active portion of growth hormone releasing hormone (GHRH). Consisting of the first 29 amino acids of the 44-amino acid native GHRH molecule, it retains full biological potency for stimulating pituitary GH release.

Research Applications

GH deficiency diagnostics, pediatric growth research, anti-aging and GH restoration studies, and pituitary function assessment.

Dosage Information (Research Use)

Historical clinical protocols: 100-300 mcg subcutaneously, typically at bedtime. Research use only.

Reconstitution & Handling

Standard BAC water reconstitution. More fragile than modified GHRH analogs — handle carefully and use promptly after reconstitution.

Half-Life & Pharmacokinetics

Approximately 10-20 minutes — significantly shorter than modified GHRH analogs due to DPP-IV degradation.

Reported Observations in Literature

Extensive safety data from clinical use: injection site reactions, facial flushing, headache. Generally well-tolerated.

Key Research References

  • Prakash A, Goa KL. “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.” BioDrugs. 1999

How Sermorelin Works

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of human GHRH (which is 44 amino acids total). These 29 residues contain the full biological activity of native GHRH. It stimulates GH release by acting on GHRH receptors on pituitary somatotrophs. As the unmodified native sequence, it is subject to rapid DPP-IV enzymatic degradation, resulting in a shorter half-life compared to modified analogs like CJC-1295.

Research Findings

Historically significant as the first synthetic GHRH analog with FDA approval (as a diagnostic agent for GH deficiency). Has extensive clinical safety data from decades of use. Often considered the most physiological GHRH-based research compound due to its identical sequence to the native hormone fragment.

Dosage & Administration

Historical clinical protocols: 100-300 mcg subcutaneously, typically at bedtime. Research use only.

Safety & Side Effects

Extensive safety data from clinical use: injection site reactions, facial flushing, headache. Generally well-tolerated.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Molecular Weight 3357.93 g/mol
Half-Life Approximately 10-20 minutes — significantly shorter than modified GHRH analogs due to DPP-IV degradation.
Available Sizes 2mg, 5mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C, use within 14 days.

Key Research References

  • Prakash A, Goa KL. "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency." BioDrugs. 1999

Related Peptides

View all →
MGF
Growth
Splice variant of IGF-1 produced in response to mechanical stress, researched for satellite cell activation and local tissue…
View Profile →
Follistatin-344
Growth
Myostatin-binding glycoprotein researched for muscle growth potential by neutralizing growth-limiting signals.
View Profile →
AOD-9604
Growth
Modified fragment of human growth hormone (hGH 176-191) researched specifically for fat metabolism without GH-related side effects.
View Profile → Buy Now